A New Two-Drug Combo Could Cut Kidney Cancer Relapse Risk by 28%—Here's What Patients Need to Know

A new combination treatment is offering hope to kidney cancer patients at high risk of relapse after surgery. Researchers found that combining an oral medication called belzutifan with the immunotherapy drug pembrolizumab significantly improved disease-free survival in patients with clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer. The findings come from a large international study presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco.

What Did the Study Show About Kidney Cancer Relapse?

The LITESPARK-022 study included 1,841 participants with ccRCC who had surgery to remove their tumors and showed no signs of cancer at the start, but faced a high risk of recurrence. Researchers randomly assigned patients to receive either the two-drug combination or pembrolizumab with a placebo after surgery. After a median follow-up of 28.4 months, the results were striking: 81% of patients taking the combination remained cancer-free, compared to 74% of those receiving standard care alone. This represents a 28% decrease in recurrence risk.

"A significant percentage of patients with high risk kidney cancer will recur within five years after surgery because microscopic cancer cells can remain undetected. We need new therapies that can work together to better prevent the cancer from coming back," explained Dr. Toni Choueiri, Director of the Lank Center for Genitourinary Cancer at Dana-Farber Cancer Institute, who led the research.

How Do These Two Drugs Work Together to Fight Cancer?

The combination works through two different mechanisms to attack cancer cells. Pembrolizumab is an immune checkpoint inhibitor, which means it helps your immune system recognize and fight cancer cells more effectively. However, pembrolizumab alone isn't enough for everyone—about 1 in 5 patients who take it will still experience a relapse.

Belzutifan, the second drug, takes a different approach. It blocks a protein called HIF-2 alpha, which is overabundant in kidney cancer cells and drives their growth. By combining these two strategies—boosting immune response while simultaneously blocking a key cancer growth pathway—the drugs work synergistically to prevent microscopic cancer cells from developing into full-blown tumors.

The science behind belzutifan is particularly noteworthy: Dr. William G. Kaelin Jr., a researcher at Dana-Farber, won the Nobel Prize in Physiology or Medicine in 2019 for the foundational work that led to belzutifan's development.

Steps to Understanding Your Treatment Options After Kidney Cancer Surgery

• Assess Your Recurrence Risk: Talk with your oncologist about whether you fall into the high-risk category for kidney cancer relapse after surgery. This determination is based on factors like tumor size, grade, and stage at the time of diagnosis.
• Learn About Pembrolizumab Alone: Previous research showed that pembrolizumab as a single agent reduced the risk of death and disease progression for advanced kidney cancer patients after surgery, making it the previous standard of care for high-risk patients.
• Discuss the New Combination Option: Ask your doctor whether the belzutifan plus pembrolizumab combination might be appropriate for your specific situation, given these new study results showing improved disease-free survival rates.
• Understand Side Effect Profiles: In the LITESPARK-022 study, side effects from the combination were consistent with what researchers had seen in previous studies, suggesting the treatment is generally well-tolerated, though you should discuss specific risks with your care team.

What Does This Mean for Kidney Cancer Patients?

For patients with high-risk ccRCC, this finding represents a meaningful advance. The 7-percentage-point improvement in cancer-free survival (from 74% to 81%) may sound modest, but it translates to real lives saved and recurrences prevented. The study has not yet collected enough long-term data to determine whether the combination also helps patients live longer overall, but disease-free survival is an important intermediate goal that often correlates with better long-term outcomes.

"People at high risk of ccRCC coming back after surgery may have a new option to reduce that risk," said Dr. Choueiri. "In this study, belzutifan, in combination with pembrolizumab, reduces the chance of recurrence compared with the current standard treatment of pembrolizumab alone."

The timing of this research is significant because kidney cancer remains a challenging disease to manage. Many patients develop recurrence even after successful surgery, which is why finding better preventive strategies after surgery is so important. This combination approach offers a new standard that could become the new benchmark for treating high-risk patients in the coming years.